Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.87 | N/A | +28.10% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.87 | N/A | +28.10% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Sarepta Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 5.81%. The company did not provide revenue figures or future guidance, but management's comments suggest a focus on ongoing projects. Investors may view the EPS surprise as a sign of potential stability in the company's financials.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN INTL GROUP
Aug 3, 2015